Subject(s)
Bone Marrow/metabolism , Multiple Myeloma/genetics , Natural Killer T-Cells/metabolism , RANK Ligand/genetics , Adult , Aged , Aged, 80 and over , Bone Marrow/immunology , Bone Marrow/pathology , Bone Marrow Cells/metabolism , Bone Marrow Cells/pathology , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Multiple Myeloma/immunology , Multiple Myeloma/metabolism , Multiple Myeloma/pathology , Natural Killer T-Cells/pathology , Up-Regulation/geneticsSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Large B-Cell, Diffuse/diagnostic imaging , Mediastinal Neoplasms/diagnostic imaging , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Mediastinal Neoplasms/drug therapy , Mediastinal Neoplasms/mortality , Middle Aged , Positron-Emission Tomography , Prednisone/administration & dosage , Prognosis , Rituximab/administration & dosage , Tomography, X-Ray Computed , Vincristine/administration & dosageSubject(s)
Anticoagulants/adverse effects , Depression, Postpartum/complications , Gastrointestinal Hemorrhage/chemically induced , Hemoglobinuria, Paroxysmal/complications , Heparin, Low-Molecular-Weight/adverse effects , Lupus Erythematosus, Systemic/diagnosis , Pregnancy Complications, Hematologic/drug therapy , Adult , Female , Gastrointestinal Hemorrhage/complications , Hemoglobinuria, Paroxysmal/drug therapy , Humans , Lupus Erythematosus, Systemic/complications , PregnancyABSTRACT
BACKGROUND: The International Staging System (ISS) is the most widely used staging system for patients with multiple myeloma (MM). However, serum ß2-microglobulin increases in renal impairment (RI) and there have been concerns that ISS-3 stage may include 'up-staged' MM patients in whom elevated ß2-microglobulin reflects the degree of renal dysfunction rather than tumor load. PATIENTS AND METHODS: In order to assess the impact of RI on the prognostic value of ISS, we analyzed 1516 patients with symptomatic MM and the degree of RI was classified according to the Kidney Disease Outcomes Quality Initiative-Chronic Kidney Disease (CKD) criteria. RESULTS: Forty-eight percent patients had stages 3-5 CKD while 29% of patients had ISS-1, 38% had ISS-2 and 33% ISS-3. The frequency and severity of RI were more common in ISS-3 patients. RI was associated with inferior survival in univariate but not in multivariate analysis. When analyzed separately, ISS-1 and ISS-2 patients with RI had inferior survival in univariate but not in multivariate analysis. In ISS-3 MM patients, RI had no prognostic impact either in univariate or multivariate analysis. Results were similar, when we analyzed only patients with Bence-Jones >200 mg/day. CONCLUSIONS: ISS remains unaffected by the degree of RI, even in patients with ISS-3, which includes most patients with renal dysfunction.
Subject(s)
Multiple Myeloma/blood , Multiple Myeloma/pathology , Neoplasm Staging/methods , beta 2-Microglobulin/blood , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Multiple Myeloma/complications , Prognosis , Renal Insufficiency/blood , Renal Insufficiency/complications , Young AdultABSTRACT
BACKGROUND/AIMS: Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) share the same acquired lesion JAK2(V617F) and may exhibit substantial overlap. Variability in JAK activation and allele burden, complemented by host, genetic and non-genetic modifiers, determine the phenotype. The aim of this study was to investigate the presence of the JAK2 mutation in association with the ratio of metallopeptidases inhibitors (TIMPs) to tissue metallopeptidases (MMPs) in MPNs, where inhibitory rather than proteolytic activity in marrow microenvironment appears to predominate. METHODS: 94 patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis, and 102 healthy individuals were evaluated. Allele-specific PCR and RFLP were used to detect JAK2 and genomic status. Serum concentrations of MMP and TIMP were measured by ELISA. The parameters were assessed with covariance analysis, and adjusted for gender, age and co-morbidity. RESULTS: Mutation frequency was 81.91%. Abnormal TIMP/MMP ratios were identified in all three diseases. JAK2 mutation was correlated with significant changes in TIMP concentrations. CONCLUSIONS: Identification of an abnormal TIMP/MMP ratio in all three diseases, regardless of the JAK2 status, indicates invariable marrow remodeling. In this particular group of patients, presence of a JAK2(V617F) mutation, being associated with even higher ratios, appears to be a concurring participant in bone marrow-reforming processes. Additional research may delineate correlates with the JAK2 allelic burden.
Subject(s)
Genes, abl , Janus Kinase 2/genetics , Matrix Metalloproteinases/metabolism , Mutation , Myeloproliferative Disorders/metabolism , Protease Inhibitors/pharmacology , Aged , Female , Humans , Hydrolysis , Male , Matrix Metalloproteinase Inhibitors , Middle Aged , Myeloproliferative Disorders/enzymology , Myeloproliferative Disorders/geneticsABSTRACT
CD4(+)CD25(+)FOXP3(+) T regulatory cells (T(regs)) prevent autoimmunity by restricting overexuberant immune responses, but the same subpopulation can incur detrimental effects on antitumor responses. In both cases, the suppressor potential of T(regs) appears to be strongly influenced by their compartmentalization. In myelodysplastic syndromes (MDS), immune deregulation and autoimmunity in the early stages might lead to ineffective hematopoiesis and bone marrow (BM) failure, whereas late-stage disease is characterized by the immune escape of the malignant clone. We show that these two stages of MDS are associated with differential T(reg) activity. Specifically, we found that in early stage MDS, compared with normal hematopoiesis and late stage MDS, T(regs) are dysfunctional and their BM homing through the CXCL12/CXCR4 axis is seriously impaired as a result of CXCR4 downregulation. Conversely, in late stage MDS, T(regs) are systemically and locally expanded and retain their function and migratory capacity. Moreover, T(reg) levels follow the disease course and are significantly reduced in treatment responding patients. Our findings indicate T(reg) involvement in the pathophysiology of MDS; defective suppressor function and BM trafficking of T(regs) may be important in the autoimmune process of early MDS, but increased T(reg) activity could favor leukemic clone progression in late stage disease.
Subject(s)
Bone Marrow/pathology , Chemokine CXCL12/physiology , Myelodysplastic Syndromes/pathology , Receptors, CXCR4/physiology , Receptors, Lymphocyte Homing/physiology , T-Lymphocytes, Regulatory/pathology , Adult , Aged , Aged, 80 and over , Autoimmunity , Blood Cells/pathology , Bone Marrow/immunology , Cell Division , Cell Transformation, Neoplastic/immunology , Chemotaxis, Leukocyte , Clone Cells/pathology , Disease Progression , Female , Humans , Immunologic Surveillance , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/immunology , Leukemia, Myeloid/pathology , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/physiopathology , Neoplastic Stem Cells/pathology , Receptors, CXCR4/genetics , T-Lymphocytes, Regulatory/immunologyABSTRACT
It is known that the presence of hemoglobin S (HbS) affects the determination of hemoglobin A(2) (HbA(2)) levels in clinical samples. We quantitated this effect using the Menarini HA-8160 analyzer and compared with other instruments (HELENA beta-thal quik column, TOSOH HLC-723G7 and BIORAD Variant II) using the HELENA SAS-MX alkaline gel electrophoresis kit as the reference method. The %HbA(2) values from the HA-8160 analyzer and the alkaline gel electrophoresis show a good linear correlation in the absence of HbS. A strong positive bias in the %HbA(2) values from the HA-8160 is apparent in the presence of HbS in the samples, when compared with the alkaline electrophoresis. The analytical imprecision and bias of the three HPLC instruments are comparable both in the presence and absence of HbS. The manual column method shows a lower bias in the absence of HbS but is more affected when HbS is present in the samples.
Subject(s)
Hemoglobin A2/analysis , Hemoglobin, Sickle/analysis , Automation, Laboratory , Chromatography, High Pressure Liquid , Chromatography, Ion Exchange , Electrophoresis, Capillary , False Positive Reactions , Hemoglobin A2/isolation & purification , Humans , Reagent Kits, Diagnostic , Reproducibility of ResultsABSTRACT
Approximately half of essential thrombocythemia (ET) patients and almost all with polycythemia vera (PV) bear the activating JAK2617V>F point mutation, which arises at the multipotent haemopoietic progenitor cell level. Although ET is mainly characterized by megacaryocyte proliferation, the cases that are positive for the JAK2617V>F mutation also show increased bone marrow cellularity and higher erythrocyte and granulocyte counts. After establishing short- and long-term bone marrow cultures we found that the frequency of committed haemopoietic progenitors in the bone marrow, was not increased in JAK2617V>F positive ET compared to the negative ones, whereas in long-term cultures (LTBMC) JAK2617V>F positive ET display a growth pattern more similar to that observed in LTBMC produced by PV marrow cells. Our data support the notion that JAK2617V>F positive ET and PV represents a continuum spectrum of alterations within the same disease.
Subject(s)
Hematopoiesis/genetics , Janus Kinase 2/genetics , Point Mutation , Thrombocythemia, Essential/genetics , Amino Acid Substitution , Cells, Cultured , Hematopoietic Stem Cells/pathology , Humans , Polycythemia Vera/pathology , Thrombocythemia, Essential/pathologyABSTRACT
BACKGROUND: The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas. PATIENTS AND METHODS: Epidemiological and clinical features of 97 patients with MALT lymphoma from the Hellenic Cooperative Oncology Group registry were analysed retrospectively for their prognostic significance in progression-free survival (PFS) and overall survival (OS). Comparisons were made between patients with gastric and nongastric sites of primary lymphoma and between different therapeutic modalities. RESULTS: Sixty-five patients presented with gastric and 32 with nongastric lymphomas. The most frequent locations of nongastric lymphomas were the bowel, lung and parotid. Gastric lymphomas occurred more frequently in males and younger patients compared with nongastric lymphomas. Seventy-four per cent of patients had early (Ann Arbor stages I-II) and 26% had advanced (stages III-IV) disease. The median PFS for the entire population was 44 months. At 5 years, 47% of patients were progression free and the OS rate was 80%. The most reliable prognostic factor for PFS and OS was the Ann Arbor stage; 5-year PFS was 67% versus 13% and 5-year OS 91% versus 51% for patients with early versus advanced disease, respectively (P < 0.001). Of the patients treated with chemotherapy only, 87% achieved an objective response and 71% complete response. Surgery did not offer survival benefit compared with chemotherapy in localised gastric lymphoma. CONCLUSION: MALT lymphomas represent a distinct disease entity with widespread extranodal origin, indolent clinical course and high chemosensitivity. Ann Arbor stage was the most reliable prognostic and predictive factor.
Subject(s)
Lymphoma, B-Cell, Marginal Zone/diagnosis , Lymphoma, B-Cell, Marginal Zone/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Analysis of Variance , Chemotherapy, Adjuvant , Disease-Free Survival , Female , Greece/epidemiology , Humans , Kaplan-Meier Estimate , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Lymphoma, B-Cell, Marginal Zone/drug therapy , Lymphoma, B-Cell, Marginal Zone/epidemiology , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, B-Cell, Marginal Zone/surgery , Male , Middle Aged , Neoplasm Staging , Parotid Neoplasms/diagnosis , Parotid Neoplasms/therapy , Prognosis , Proportional Hazards Models , Registries , Retrospective Studies , Risk Factors , Severity of Illness Index , Stomach Neoplasms/diagnosis , Stomach Neoplasms/therapySubject(s)
Hydroxyurea/administration & dosage , Polycythemia Vera/drug therapy , Quinazolines/administration & dosage , Thrombocythemia, Essential/drug therapy , Adult , Aged , Aged, 80 and over , Drug Resistance , Drug Therapy, Combination , Female , Humans , Hydroxyurea/adverse effects , Male , Middle Aged , Quinazolines/adverse effectsABSTRACT
BACKGROUND: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lymphomas. In a secondary analysis we evaluated the impact of adding rituximab to CEOP-14/CEOP-21 chemotherapy. STUDY DESIGN: The trial opened in March 1999, and patients were randomly assigned to either CEOP-14 or CEOP-21. All patients enrolled from May 2002 onward received rituximab with each chemotherapy cycle, and those attaining a complete response received rituximab consolidation. RESULTS: Complete and overall response rates in the CEOP-21 +/- rituximab (N = 114) and CEOP-14 +/- rituximab (N = 103) arms were similar, as were the overall survival (P = 0.769) and time to progression distributions (P = 0.969). Rituximab was shown to have a beneficial effect both on the overall survival and on the time to progression. CONCLUSIONS: Thus far, no significant improvement in outcome has been demonstrated with CEOP-14 +/- rituximab versus CEOP-21 +/- rituximab. However, with addition of rituximab to CEOP-21/CEOP-14, significant improvements in time to progression and overall survival were achieved.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use , Epirubicin/adverse effects , Epirubicin/therapeutic use , Female , Humans , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/pathology , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/pathology , Lymphoma, Non-Hodgkin/pathology , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/pathology , Male , Middle Aged , Prednisone/adverse effects , Prednisone/therapeutic use , Rituximab , Vincristine/adverse effects , Vincristine/therapeutic useSubject(s)
Antineoplastic Agents/administration & dosage , Boronic Acids/administration & dosage , Peritoneal Neoplasms/therapy , Plasmacytoma/therapy , Pyrazines/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bortezomib , Combined Modality Therapy/methods , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Humans , Injections, Intravenous , Lymph Nodes/diagnostic imaging , Male , Middle Aged , Peritoneal Neoplasms/diagnostic imaging , Plasmacytoma/diagnostic imaging , Radiotherapy Dosage , Stem Cell Transplantation , Tomography, X-Ray Computed/methods , Transplantation, AutologousABSTRACT
The purpose of this retrospective study, the largest unselected series in our country, was to illustrate the clinicopathological features of non-Hodgkin's lymphoma (NHL) classified according to the World Health Organization (WHO) classification of lymphoid neoplasms. A retrospective analysis was conducted and clinical features of histological subtypes were established in 810 patients (age > or = 15 years) with NHL who were treated at 8 major centers representative of Greece. There were 435 males and 375 females 95% of them aged >30 years. B symptoms were present in 34% of the patients, while 45.3% had stages I-II and 54.6% had stages III-IV. LDH was increased in 37% of the patients. B cell lymphomas formed 88% of the cases whereas T cell lymphomas formed 12% of the total. Indolent lymphomas accounted for 31.1%, aggressive ones for 66.7% and very aggressive ones for 2.4% of all NHLs. Among indolent lymphomas extranodal ones (MALT B cell lymphoma) were the most common subset while follicular lymphoma grade I and II and small lymphocytic ones presented with equal frequency. Among the aggressive lymphomas diffuse large cell lymphoma (DLCL) was the most common subtype; this entity along with large-cell immunoblastic lymphomas accounted for 45.2% of all B cell lymphomas. Among the T cell lymphomas, peripheral T cell lymphomas and anaplastic large cell lymphomas of the T/null-cell type were the most common subtypes. The most common extranodal presentation was the gastrointestinal tract (GI). Next in frequency were primary extranodal NHL of the head and neck region. MALT B cell lymphomas were found in almost half of the patients with GI tract NHL, whereas in all other extranodal places DLCL was the predominant histological subtype. The median survival for indolent and aggressive NHL was 123.5 and 55.5 months, respectively. This is the first report of a large series of malignant lymphomas in Greece using the WHO classification. It appears that there are no significant differences between NHL in Greece and other large series as far as clinical and extranodal presentation is concerned. The frequency of follicular lymphoma in the current study is comparable to that reported from Asian countries and mainland Europe, but lower than that of US and Northern European series. There were no important differences in the incidence of the remaining histological subtypes between Greece and other European countries.
Subject(s)
Gastrointestinal Neoplasms/classification , Head and Neck Neoplasms/classification , Lymphoma, Large B-Cell, Diffuse/classification , Lymphoma, T-Cell, Peripheral/classification , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Gastrointestinal Neoplasms/epidemiology , Gastrointestinal Neoplasms/mortality , Gastrointestinal Neoplasms/pathology , Greece/epidemiology , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/pathology , Humans , Lymphoma, Large B-Cell, Diffuse/epidemiology , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, T-Cell, Peripheral/epidemiology , Lymphoma, T-Cell, Peripheral/mortality , Lymphoma, T-Cell, Peripheral/pathology , Male , Middle Aged , Neoplasm Staging , Retrospective Studies , World Health OrganizationABSTRACT
Lymph node infiltration by monoclonal plasma cells can occur either in aggressive forms of myeloma or may represent regional extension of extramedullary plasmacytomas, whereas lymph node plasmacytoma presenting as a solitary extramedullary plasmacytoma is very unusual. We report two cases of lymph node plasmacytomas without systemic disease diagnosed after surgical excision. Clinical remission was achieved after local radiotherapy although one patient relapsed with multifocal extramedullary plasmacytomas 20 months after radiotherapy.
Subject(s)
Plasmacytoma/pathology , Abdominal Neoplasms/pathology , Aged , Humans , Male , Middle Aged , Neoplasm Invasiveness , Plasma Cells/pathology , Plasmacytoma/diagnosis , Plasmacytoma/therapy , Retroperitoneal Neoplasms/pathology , Tomography, X-Ray ComputedABSTRACT
To evaluate the activity of thalidomide in Waldenstrom's macroglobulinemia (WM), 20 patients were treated on a dose schedule that escalated from 200 mg/d to 600 mg/d. On an intention-to-treat basis, five (25%) patients achieved a partial response, which was noted within 3 months of treatment. Adverse effects were common and prevented dose escalation of thalidomide in 75% of patients and led to premature discontinuation of treatment in 35%. We subsequently evaluated the oral combination of clarithromycin (500 mg twice per day), low-dose thalidomide (200 mg once daily), and dexamethasone (40 mg once per week). Our preliminary analysis on 12 previously treated patients indicate activity of this regimen in WM: three patients achieved a partial response and two patients demonstrated monoclonal protein reduction of greater than 25%. This combination was associated with a variety of side effects due not only to thalidomide, but also to corticosteroids and to clarithromycin. Our preliminary data indicate that this combination may be a useful salvage regimen for some patients with heavily pretreated macroglobulinemia.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Thalidomide/therapeutic use , Waldenstrom Macroglobulinemia/drug therapy , Clarithromycin/administration & dosage , Clinical Trials, Phase II as Topic , Dexamethasone/administration & dosage , Humans , Thalidomide/administration & dosageABSTRACT
Advanced stage mycosis fungoides (MF) generally has a poor prognosis, and currently there is no standard treatment available. Here we report the case of a young woman with recalcitrant tumour-stage MF (T3, stage IIb) whose disease was unresponsive to several therapeutic modalities, but who has showed sustained clinical response to pegylated liposomal doxorubucin. No severe infectious complications have been observed. The use of this drug in tumour-stage MF should be investigated further.
Subject(s)
Antineoplastic Agents/therapeutic use , Doxorubicin/therapeutic use , Mycosis Fungoides/drug therapy , Skin Neoplasms/drug therapy , Adult , Female , Humans , Liposomes , Remission InductionABSTRACT
INTRODUCTION: During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile. In particular, M has less severe non-hematological toxicity. PATIENTS AND METHODS: A randomized multicenter phase III study was conducted in order to compare the efficacy and toxicity of CEOP and CNOP in intermediate- and high-grade NHL. CEOP (arm A) consisted of cyclophosphamide 1000mg m(-2), vincristine 2mg, E 70mg m(-2) on day 1 and prednisone 60mg on days 1-7. The CNOP regimen (arm B) was identical to CEOP except for replacement of E by M at a dose of 12mg m(-2). Randomization was stratified according to stages I-IV. From September 1993 to March 1999, 249 patients registered for the trial. Patient characteristics were equally distributed in the two arms, except for age and International Prognostic Index (IPI) groups. RESULTS: There were no significant differences between the two groups in the rates of complete (CR) and partial response (PR). The overall response rate was 78% in arm A (57% CR, 21% PR) and 82% in arm B (60% CR, 22% PR). With a median follow-up time of 47.3 months, the median survival was not reached in arm A, while it was 39.5 months in arm B (P=0.09). Three-year survival rates were 62.5% for CEOP and 51.5% for CNOP. There was no significant difference regarding the time to progression between the two groups (29.7 vs. 18.5 months); furthermore the median duration of CRs was 71.6 and 49 months for CEOP and CNOP, respectively (P=0.07). The therapeutic efficacies of both regimens were equivalent among the four IPI groups. More alopecia was observed in arm A. WHO grade >2 neutropenia was more frequent in arm B. Supportive treatment with G-CSF was given to 22 and 24 patients, respectively. CONCLUSION: There were no significant differences in terms of overall response rates, overall survival and time to progression between CEOP and CNOP in the treatment of intermediate- and high-grade NHL. Patients with low or low intermediate IPI risk treated with either CEOP or CNOP showed significantly better survival, response rates and time to progression than those with high intermediate or high IPI risk. Therefore, new improved therapeutic approaches should be developed for the treatment of high IPI risk patients.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclophosphamide/therapeutic use , Epirubicin/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Mitoxantrone/therapeutic use , Prednisolone/therapeutic use , Prednisone/therapeutic use , Vincristine/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Alopecia/chemically induced , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cyclophosphamide/adverse effects , Epirubicin/adverse effects , Granulocyte Colony-Stimulating Factor/therapeutic use , Humans , Lymphoma, Non-Hodgkin/mortality , Middle Aged , Mitoxantrone/adverse effects , Neutropenia/chemically induced , Prednisolone/adverse effects , Prednisone/adverse effects , Remission Induction , Survival Rate , Treatment Outcome , Vincristine/adverse effectsSubject(s)
Immunoblastic Lymphadenopathy/drug therapy , Vidarabine/analogs & derivatives , Vidarabine/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Disease-Free Survival , Drug Administration Schedule , Humans , Immunoblastic Lymphadenopathy/classification , Immunoblastic Lymphadenopathy/diagnosis , Lymphoma, T-Cell/classification , Lymphoma, T-Cell/diagnosis , Lymphoma, T-Cell/drug therapy , Male , Middle Aged , Treatment OutcomeABSTRACT
Non-African Burkitt's lymphoma is a rare disease among adults without AIDS. Among 1352 Greek adult patients with non-Hodgkin's lymphoma, 24 cases (1.8%) were classified as Burkitt's (BL) or Burkitt-like (BLL) lymphoma. Eleven cases fulfilled the criteria of BL and 13 of BLL. No statistical differences were found in the general characteristics of the two groups at the time of diagnosis. Extranodal involvement was a common finding in both groups and bulky disease (>10 cm) was observed in almost one half of the patients. The majority of the patients were treated with intensive, although different, protocols. After induction treatment, complete remission (CR) was achieved in 14 patients (60.8%). CR was reached in all cases with stage I-II, while in stage IV the CR rate was 30.4%. The median overall survival was 27 months. The median survival for BL was 13 months compared to 27 months in the BLL group (P=0.34). The data of the present retrospective analysis, indicated that there were not significant clinical differences between BL and BLL variants. Since BLL is still a non-reproducible category in the REAL classification, all BL variants must be treated uniformly with intensive protocols.